InSphero Appoints Werner Lanthaler to Its Board of Directors
InSphero AG, the pioneer in scalable 3D in vitro technologies for drug safety and efficacy testing, announced the appointment of Dr. Werner Lanthaler, Managing Director of Wlanholding GmbH, former Chief Executive Officer of Evotec SE, and former CFO of Intercell AG, to its Board of Directors.
Dr. Lanthaler led Evotec for 16 years, during which he guided the company’s transformation into a global leader in drug discovery solutions. His appointment to InSphero’s Board underscores the company’s growing recognition as a driving force in industry-ready in vitro solutions for preclinical testing.
“We are thrilled to welcome Werner Lanthaler to our Board,” said Dr. Jan Lichtenberg, CEO and Co-founder of InSphero. “His vision has shaped the drug discovery field for more than a decade. Werner’s experience will be invaluable as we continue to scale our technologies, expand our partnerships, and further expand InSphero’s leadership in scalable, reliable, and reproducible 3D in vitro solutions.”
InSphero’s 3D InSight™ platforms are increasingly recognized as essential New Approach Methodologies (NAMs) for drug development. With the FDA and NIH reaffirming their commitment to human-relevant models, InSphero is advancing its mission to democratize access to NAMs and accelerate the global transition toward more efficient and ethical drug discovery.
“I have been impressed by InSphero’s scientific excellence and their determination to transform the way drugs are developed,” said Dr. Werner Lanthaler. “The company’s platforms deliver the scalability and reproducibility the industry urgently needs to reduce reliance on animal models. I look forward to supporting InSphero in making these solutions accessible to researchers worldwide.”
With Dr. Lanthaler joining the Board, InSphero strengthens its strategic capabilities at a pivotal moment for the industry. The company will continue to build on its strong foundation to help pharmaceutical and biotech partners unlock the full potential of 3D in vitro solutions for safer, faster, and more patient-relevant therapies.